Welcome to our dedicated page for Personalis news (Ticker: PSNL), a resource for investors and traders seeking the latest updates and insights on Personalis stock.
Personalis, Inc. reports recurring developments in advanced genomics for precision oncology, with emphasis on personalized cancer testing, minimal residual disease monitoring and sequencing-based data analysis services. Company updates frequently center on the NeXT Personal ultrasensitive ctDNA assay, clinical test volume, clinical revenue, Medicare coverage for breast and lung cancer surveillance, and the shift toward commercial adoption of MRD testing.
News also covers clinical data presentations and publications in oncology settings, including breast, lung and colorectal cancer, as well as product features such as Real-Time Variant Tracker for therapy-resistance monitoring. Other recurring items include quarterly results, financial guidance, biopharma research applications and governance or management changes tied to the company’s precision oncology strategy.
Personalis (Nasdaq: PSNL) reported new analysis from the AstraZeneca phase 3 LAURA trial showing that the NeXT Personal® ultrasensitive MRD test can monitor maintenance treatment response after chemoradiotherapy in unresectable stage III, EGFR-mutated NSCLC.
Key findings: Osimertinib treatment led to MRD clearance in most patients with post-CRT MRD, and NeXT Personal detected MRD progression with a median 5-month lead time ahead of Blinded Independent Central Review (BICR) assessed progression. The LAURA results will be presented at ESMO 2025. Prior studies cited include CALLA (detection up to ~16 months before imaging) and NeoADAURA.
Personalis (Nasdaq: PSNL), a precision oncology genomics company, has granted inducement stock options to its newly appointed Senior Vice President and Chief Information Officer. The award includes options to purchase 440,000 shares of common stock at $5.93 per share under the company's 2020 Inducement Plan.
The stock options have a four-year vesting schedule, with 25% vesting after one year and the remaining vesting monthly over the following three years. This grant complies with Nasdaq Rule 5635(c)(4) for new employee equity incentives.
Personalis (Nasdaq: PSNL) has announced a collaboration with Yale Cancer Center for the CATE clinical trial, focusing on ctDNA-guided treatment in breast cancer. The trial will utilize Personalis's NeXT Personal® test to detect early molecular signs of recurrence in HR+/HER2- breast cancer patients.
The prospective, multi-center trial aims to prevent metastatic relapse by using ultrasensitive ctDNA detection to guide early intervention with elacestrant therapy. The study specifically targets HR+/HER2- breast cancer, which represents over 70% of all breast cancer cases and carries a significant risk of late recurrence.
Personalis (Nasdaq: PSNL) has announced significant new data from AstraZeneca's phase 3 NeoADAURA trial, demonstrating the superior performance of its NeXT Personal® MRD test in lung cancer patients. The study focused on patients with stage II-IIIb, EGFR-mutated non-small cell lung cancer receiving neoadjuvant therapy.
The test showed higher baseline sensitivity for ctDNA detection compared to other gene-mutation based tests, proved to be strongly prognostic of clinical outcomes, and demonstrated association with major pathological response. Notably, the test detected cancer DNA up to 16 months ahead of standard imaging in cervical cancer patients. The company has recently submitted for Medicare coverage for NeXT Personal in lung cancer patients.
Personalis (Nasdaq: PSNL), a precision oncology genomics company, has announced its management team's participation in two upcoming investor conferences in New York. The company will attend the Morgan Stanley 23rd Annual Global Healthcare Conference on September 10, 2025, at the Sheraton New York Times Square Hotel, and the Lake Street 9th Annual Best Ideas Growth Conference on September 11, 2025, at the Yale Club.
Personalis (Nasdaq: PSNL) reported Q2 2025 financial results, highlighting a 59% sequential growth in clinical test volume to 3,478 tests. However, revenue declined 24% year-over-year to $17.2 million. The company expanded its partnership with Tempus AI to include colorectal cancer and presented significant clinical data at ASCO 2025.
Q2 financial metrics showed a gross margin of 27.6% and a net loss of $20.1 million. The company ended the quarter with $173.2 million in cash. Personalis revised its full-year 2025 guidance downward, now expecting revenue between $70-80 million, with increased projected net loss of approximately $85 million.
Personalis (Nasdaq: PSNL), a genomics company focused on cancer research, has scheduled the release of its Q2 2025 financial results for Tuesday, August 5, 2025. The company will host a conference call and webcast at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time on the same day.
Investors can join via phone using the following dial-in numbers: 877-451-6152 (domestic) or 201-389-0879 (international). A webcast will be available in the Events section at investors.personalis.com, with a replay archived on the website after the call.
Personalis (Nasdaq: PSNL), a precision oncology genomics company, has granted an inducement stock option to its newly appointed Vice President, Corporate Controller. The option allows for the purchase of 100,000 shares of common stock at an exercise price of $6.31 per share, matching the closing price on July 15, 2025.
The stock option, granted under Personalis' 2020 Inducement Plan, follows a four-year vesting schedule with 25% vesting after one year and the remaining portions vesting monthly over the following three years, contingent on continued employment.
Personalis (Nasdaq: PSNL) has expanded and extended its strategic collaboration with Tempus AI through 2029, adding colorectal cancer (CRC) as the fourth indication for their NeXT Personal® minimal residual disease (MRD) test. The test will now cover breast, lung, and colorectal cancers, plus solid tumor immunotherapy monitoring.
The expansion follows promising interim results from the VICTORI study presented at AACR 2025, showing strong performance in detecting early CRC recurrence. The collaboration leverages Tempus' extensive network reaching over 50% of U.S. oncologists to accelerate the adoption of Personalis' ultra-sensitive cancer recurrence detection technology.